We have worked with the Netherlands Cancer Institute for over 7 years and our collaboration continues to yield new targets for therapeutic intervention. Prolifix, based in Abingdon, Oxfordshire, UK, is a privately owned pharmaceutical company. It is a leader in cell cycle drug discovery and is developing a unique platform technology which enables the company to target pathologically important protein-protein interactions which control the cell cycle. Prolifix aims to discover and develop novel, small molecule drugs to address diseases associated with aberrant cell cycle regulation. It is focused on cancer and infectious disorders.
Several projects are in lead optimization and one has entered pre-clinical evaluation.
Add the UniSci Daily Java News Ticker to Your Site or Desktop. Click for a demo and more information. Copyright 1995-2001 UniSci. All rights reserved.